Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Gareth M. Davies"'
Publikováno v:
SLAS Discovery. 26:524-533
Targeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis machinery to deplete specific proteins. This represents a paradigm shift in early drug discovery, away from occupancy-driven to event-driven mechanisms.Recent
Autor:
David C. Jackson, Catherine E. Hanratty, Kian Fan Chung, John G. Matthews, Ratko Djukanovic, Maria Nunez, Robert Niven, Douglas S. Robinson, Liam G Heaney, Michelle Bourne, Catherine Borg, Clare Connolly, Mary Bellamy, Val Hudson, Gareth M. Davies, Christopher E. Brightling, Beverley Hargadon, Traceyanne Grandison, Ian M. Adcock, Sebastian L. Johnston, Rekha Chaudhuri, Geraldine Jones, James Lordan, Andrew Menzies-Gow, Adnam Azim, Dominic E. Shaw, John Busby, Ashley Woodcock, Freda Yang, Peter Bradding, Christopher Corrigan, David F. Choy, Cecile T.J. Holweg, Douglas C. Cowan, Paula McCourt, Tim Harrison, Peter H. Howarth, AH Mansur, Joel Solis, Avril Horn, Joseph R. Arron, Gabrielle Gainsborough, Sarah E Davies, Stephen J. Fowler, Roisin Stone, Timothy C. Hardman, Ian D. Pavord, Samantha Walker, Richard W. Costello, Katherine C. Smith
Publikováno v:
The Lancet. Respiratory Medicine
Heaney, L G, Busby, J, Hanratty, C E, Djukanovic, R, Woodcock, A, Walker, S M, Hardman, T C, Arron, J R, Choy, D F, Bradding, P, Brightling, C E, Chaudhuri, R, Cowan, D C, Mansur, A H, Fowler, S J, Niven, R M, Howarth, P H, Lordan, J L, Menzies-Gow, A, Harrison, T W, Robinson, D S, Holweg, C T J, Matthews, J G & Pavord, I D 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Investigators for the MRC Refractory Asthma Stratification Programme 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet. Respiratory medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Heaney, L G, Busby, J, Hanratty, C E, Djukanovic, R, Woodcock, A, Walker, S M, Hardman, T C, Arron, J R, Choy, D F, Bradding, P, Brightling, C E, Chaudhuri, R, Cowan, D C, Mansur, A H, Fowler, S J, Niven, R M, Howarth, P H, Lordan, J L, Menzies-Gow, A, Harrison, T W, Robinson, D S, Holweg, C T J, Matthews, J G & Pavord, I D 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Investigators for the MRC Refractory Asthma Stratification Programme 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet. Respiratory medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Background: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driv
Autor:
Johanna S. Rees, Samir W. Hamaia, Natalie J. Tigue, Lawrence C C Cheung, Antony P. Jackson, Gareth M. Davies, Kathryn S. Lilley, Alan Sandercock
Publikováno v:
International Journal of Oncology
The immune checkpoint protein B7-H4 plays an important role in the positive as well as the negative regulation of immune T-cell responses. When expressed on cancer cells, B7-H4 inhibits T-cell activity, and numerous types of cancer cells use upregula
Publikováno v:
ADMET and DMPK
Volume 7
Issue 4
ADMET and DMPK, Vol 7, Iss 4, Pp 222-241 (2019)
Volume 7
Issue 4
ADMET and DMPK, Vol 7, Iss 4, Pp 222-241 (2019)
Biophysical methods such as mass spectrometry, surface plasmon resonance, nuclear magnetic resonance, and both differential scanning isothermal titration calorimetry are now well established as key components of the early drug discovery process. Thes
Autor:
Lorin Roskos, Binbing Yu, Rajesh Narwal, Terrance O'Day, Judith Anderton, Gareth M. Davies, Gina DAngelo, Jay Harper, Wei Zhao, Steven Novick, Paolo Vicini, Harry Yang
Publikováno v:
Pharmaceutical Statistics. 18:688-699
Linear models are generally reliable methods for analyzing tumor growth in vivo, with drug effectiveness being represented by the steepness of the regression slope. With immunotherapy, however, not all tumor growth follows a linear pattern, even afte
Publikováno v:
SLAS discovery : advancing life sciences RD. 26(2)
Enzymes represent a significant proportion of the druggable genome and constitute a rich source of drug targets. Delivery of a successful program for developing a modulator of enzyme activity requires an understanding of the enzyme's mechanism and th
Autor:
David Murray, Geoffrey A. Holdgate, Ian Sinclair, Hannah Semple, Gareth M. Davies, Helen Plant
Publikováno v:
Protein-Ligand Interactions ISBN: 9781071611968
It is clear from the analysis of the distribution of approved drug targets that enzymes continue to be a major target class for the pharmaceutical industry. The application of high-throughput screens designed to monitor the activity of these enzyme t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ced03b07e0d52744da70e4eb6ff5eaaa
https://doi.org/10.1007/978-1-0716-1197-5_9
https://doi.org/10.1007/978-1-0716-1197-5_9
Autor:
Göran Dahl, Bernd Kappler, Anna Tigerström, Annette Brodte, Fredrik Edfeldt, Philip B. Rawlins, Anders Egnéus, Geoff Holdgate, Rutger H. A. Folmer, Gareth M. Davies, Stephan Steigele, Eva-Lotta Westberg, Stephan Heyse, Nichole O'Connell, Martin Ginkel, Per Hillertz, Alexander Mehrle
Publikováno v:
Slas Discovery
Surface plasmon resonance (SPR) is a powerful method for obtaining detailed molecular interaction parameters. Modern instrumentation with its increased throughput has enabled routine screening by SPR in hit-to-lead and lead optimization programs, and
Publikováno v:
Expert opinion on drug discovery. 14(7)
Introduction: The expansion of label free mass spectrometry into early drug discovery was always predicted to provide improvements in data quality and depth with the potential to reduce costs but has previously been limited by throughput. There are s
Autor:
Elizabeth Mouchet, Joe Olechno, Emmy Hoyes, Lucien P. Ghislain, Martin Bachman, Michael Morris, Ian Sinclair, Richard N. Ellson, Steven Derek Pringle, David Murray, Lars Majlof, Gareth Rhys Jones, Jonathan Wingfield, Daniel H. Addison, Gareth M. Davies, Sammy S. Datwani, Michael Tonge, Perdita E. Barran, Eric W. Hall, Mattias Rohman, Richard G. Stearns
Publikováno v:
Analytical chemistry. 91(6)
Mass spectrometry (MS) has many advantages as a quantitative detection technology for applications within drug discovery. However, current methods of liquid sample introduction to a detector are slow and limit the use of mass spectrometry for kinetic